Open Orphan Chairman Cathal Friel speaks to BRR Media re the new contract, other developments and the CEO’s departure
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Rosie Riall at BRR Media after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study. Cathal also covers the channel pipeline, the hVIVO quarantine centre, flu and malaria vaccines and the planned departure of CEO Trevor Phillips.
Open Orphan: Flu vaccine data showcased in peer reviewed article – Proactive Investors
by Ian Lyall. FLU-v has been developed by Imutex, 49%-owned by Open Orphan unit hVIVO The results of a successful phase IIb trial of a potential flu vaccine being developed by an Open Orphan PLC (LON:ORPH) joint-venture have been written up in a peer-reviewed article carried by a scientific journal. The data from FLU-v 004 […]
Open Orphan #ORPH – Publication of positive FLU-v vaccine challenge study results in journal
Positive results from FLU-v vaccine challenge study (FLU-v 004), the second Phase IIb study of FLU-v, which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group, have now been published in a peer review journal FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate The publication in ‘npj Vaccines’ […]
BRR Media – Cathal Friel & hVIVO Chief Scientist Andrew Catchpole discuss the Coronavirus Challenge Study and the FLU-V Vaccine
Cathal Friel & hVIVO Chief Scientist Andrew Catchpole discuss recent developments and the Coronavirus Challenge Study and the FLU-V Vaccine with the BRR Media team.
Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study
Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 […]
Open Orphan #ORPH – Publication of Positive Results in Journal
Positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003), which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate and the results have now been published in a peer review journal The publication in the Annals […]